Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

Phase 3

Not yet recruiting

• Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• Interventions: Drug: Sipuleucel-T Injection

• Registration Number: NCT06134232
• Lead Sponsor: Dendreon

Brief Summary

A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Detailed Description

Those enrolled in the Booster Study will have had their course of treatment with PROVENGE® immunotherapy and then randomized to the Booster Study to be treated with a single booster dose of sipuleucel-T.

Study Timeline

• Study First Submitted: 2023-10-18
• Status Verified: 2023-11
• Study First Submitted QC: 2023-11-10
• Last Update Submitted: 2023-11-10
• Study First Posted: 2023-11-18
• Last Update Posted: 2023-11-18
• Study Start: 2023-11-27
• Primary Completion: 2031-12-31
• Study Completion: 2032-06-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Male
• Target Recruitment: 400

Inclusion Criteria

For a subject to be eligible for participation in this study, all of the following criteria must be satisfied:

1. Potential subjects are men aged ≥18 years who are clinically indicated for treatment with PROVENGE® (asymptomatic or minimally symptomatic metastatic castrate-resistant [hormone refractory] prostate cancer).
2. Have qualified for on-label PROVENGE® infusion
3. Have received all 3 infusions of PROVENGE® prior to randomization
4. Written informed consent provided prior to the initiation of study procedures
5. Estimated life expectancy ≥12 months

Exclusion Criteria

A subject will not be eligible for participation in this study if any of the following criteria apply.

1. Men who are not clinically indicated for treatment with PROVENGE® (asymptomatic or minimally symptomatic metastatic castrate-resistant [hormone refractory] prostate cancer).

2. Need for systemic chronic immunosuppressive therapy (eg, antitumor necrosis factor alpha monoclonal antibodies, glucocorticoids).

3. Uncontrolled, concurrent illness including, but not limited to the following:ongoing or active infection (bacterial, viral, or fungal), or psychiatric illness that would limit compliance with study requirements,as well as any condition that would preclude a subject from completing PROVENGE® or sipuleucel-T treatment.

4. On experimental or investigational therapy.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Booster Arm	Sipuleucel-T Injection	Experimental: Treatment Group: Single Infusion of Sipuleucel-T (Booster) Sipuleucel-T is an autologous cellular immunotherapy available as a suspension for intravenous infusion. Subjects randomized to sipuleucel-T arm will receive 1 infusion of sipuleucel-T 6-9 months after receiving commercial Provenge. These subjects will be followed as described in the schedule of events.

Primary Outcome Measures

Name	Time	Method
Assess humoral immune response to PAP and PA2024 after booster infusion	Once all subjects have completed the study through the 5 year Overall Survival Period	To assess the humoral response ((i.e. antibody titer) to PAP and PA2024 after booster infusion in subjects with metastatic castrate-resistant prostate cancer who have received a single booster dose of sipuleucel-T vs those subjects who have not
Geometric Mean Ration of the difference in Humor Response	Once all subjects have completed the study through the 5 year Overall Survival Period	The difference in humoral response to PAP and/or PA2024 after booster infusion (measured approximately 2 weeks after receipt of booster) assessed by Geometric Mean Ratio of the difference between humoral response at each timepoint and after booster within and between the groups.Subjects will be evaluated for IgG and IgM antibody responses by an Enzyme-Linked Immunosorbent Assay (ELISA) and both the antibody titer as well as percent maintaining an antibody response, as determined by number of subjects with an antibody titer greater that the 9th percentile at baseline, will be compared between booster and control arms

Secondary Outcome Measures

Name	Time	Method
Evaluate the incidence of adverse events including laboratory abnormalities after a single booster does of sipuleucel-T	Once all subjects have completed the study through the 5 year Overall Survival Period	For all subjects enrolled in the study. Evaluation will include descriptive statistics by treatment arm and in the aggregate of the incidence of adverse events (Number of participants with adverse events (AEs), and the incidence of clinically significant laboratory abnormalities (Number of participants experiencing clinically significant laboratory abnormalities) after initial treatment and booster (Week 28) within and between groups.